Respirium, page-5

Jamwolf, you appear to be against the bid......I respect that......If it doesn't get over the line, RSH will go and speak with other smart inhaler companies.....and ADR can continue with their high cost R&D program, trying to create the required objective symptom monitoring capabilities to qualify for US Remote Patient Monitoring CPT reimbursement.

Could be an interesting sliding doors moment to reflect on in 6/12 months.

RSH offer another smart inhaler company instant access to US CPT reimbursement, and ADR commit another $10m+ to Planet Innovation for development work that may or may not succeed.